| Patents for A61K 48 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy (86,964) |
|---|
| 09/08/2004 | EP1131087B1 Methods of alleviating cancer symptoms |
| 09/08/2004 | EP1126870B1 Use of vegf-c or vegf-d gene or protein to prevent restenosis |
| 09/08/2004 | EP0991426B1 Method for transferring nucleic acid into the striated muscle |
| 09/08/2004 | EP0975370B9 Composition and method for enhancing transport across biological membranes |
| 09/08/2004 | EP0922099B1 Fas ligand-like protein, its production and use |
| 09/08/2004 | EP0892852B1 Encapsulated cells expressing cytochrome p450 for prodrug activation |
| 09/08/2004 | CN1527883A Leporipox-based vector vaccines |
| 09/08/2004 | CN1527719A Tryptophanyl-tRNA synthetase derived polypeptides useful for the regulation of angiongenesis |
| 09/08/2004 | CN1527716A Anti-virus agent |
| 09/08/2004 | CN1527698A 控释可生物降解的凝胶基质 Controlled release biodegradable gel matrix |
| 09/08/2004 | CN1526737A Molt-inhibiting hormone-1 protein of mitten crab |
| 09/08/2004 | CN1526727A Mouse tumor generating andmetastasis promoting acceptor and its encoding gene and application |
| 09/08/2004 | CN1165618C Polynucleotide immunogenic agents |
| 09/08/2004 | CN1165617C Oligonucleotides for inhibiting expression of human eg5 |
| 09/07/2004 | US6787641 Identification of sel-12 and uses thereof |
| 09/07/2004 | US6787353 Self-renewing restricted stem cells for treating neurological diseases; can differentiate into multiple neuronal but not glial phenotypes |
| 09/07/2004 | US6787351 Composition for the prevention of preferential viral infections |
| 09/07/2004 | US6787346 Kinase capable of site-specific phosphorylation of IκBα |
| 09/07/2004 | US6787335 Polynucleotides and polypeptides which are diagnostic markers for mammary gland cancer. |
| 09/07/2004 | US6787333 Retrovirus isolated from humans |
| 09/07/2004 | US6787321 Mammalian two-hybrid system for screening for modulators of the accumulation of metabolic products |
| 09/07/2004 | US6787319 Nucleotide sequences coding polypeptide for use in the treatment of alzheimer's disease |
| 09/07/2004 | US6787311 Diagnosis of premature ovarian failure |
| 09/07/2004 | CA2173594C Methods and compositions of a bioartificial kidney suitable for use in vivo or ex vivo |
| 09/02/2004 | WO2004074514A2 Method of diagnosis of type 2 diabetes and early onset thereof |
| 09/02/2004 | WO2004074509A2 Reversible attachment of a membrane active polymer to a polynucleotide |
| 09/02/2004 | WO2004074494A1 Method of treating ischemic disease |
| 09/02/2004 | WO2004074450A2 Combination therapy for treating protein deficiencies |
| 09/02/2004 | WO2004074428A2 Treatment of metabolic disorders |
| 09/02/2004 | WO2004073641A2 Induced activation in dendritic cells |
| 09/02/2004 | WO2004073624A2 Contraceptive methods and compositions related to proteasomal interference |
| 09/02/2004 | WO2004073604A2 Dna vaccines that express an adp-ribosyltransferase toxin devoid of adp-ribosyltransferase activity |
| 09/02/2004 | WO2004073603A2 Dna vaccine that expresses mutant adp-ribosyltransferase toxins which display reduced, or are devoid of, adp-ribosyltransferase activity |
| 09/02/2004 | WO2004056966A3 Methods of inhibiting gene expression by rna interference |
| 09/02/2004 | WO2004046691A3 Uncaging devices |
| 09/02/2004 | WO2004033653A3 Gene regulation with aptamer and modulator complexes for gene therapy |
| 09/02/2004 | WO2004018627A3 Methods for propagating adenovirus and virus produced thereby |
| 09/02/2004 | WO2004005464A3 Compounds promoting delivery of genes |
| 09/02/2004 | WO2003096981A3 Method of modulating angiogenesis |
| 09/02/2004 | US20040172687 Modified proteinase inhibitors |
| 09/02/2004 | US20040172667 Administration of transposon-based vectors to reproductive organs |
| 09/02/2004 | US20040171807 involves engineering a recombinant shuttle vector comprising a nucleic acid cassette encoding prokaryotic green fluorescent protein (GFP) operably linked to regulatory sequences which permit its expression in a host cell |
| 09/02/2004 | US20040171806 Modified hpv e6 and e7 genes and proteins useful for vaccination |
| 09/02/2004 | US20040171804 for drug screening cancer, osteoporosis, obesity, Alzheimer's disease drugs; genetic engineering; kits |
| 09/02/2004 | US20040171796 comprising an agonist of a majort histocompatability complex (MHC) class I binding native sequence having enhanced immunogenicity; for inhibiting or killing CEA epitope-expressing carcinoma cells; genetic engineering; kits |
| 09/02/2004 | US20040171795 capable of binding to a gene and transferring this gene into cells, have an affinity with phosphatidylserine, have a high safety and an excellent selectivity; for gene therapy/cancer treatment; genetic engineering |
| 09/02/2004 | US20040171575 Antisense modulation of interferon gamma receptor 2 expression |
| 09/02/2004 | US20040171574 Growth hormone and growth hormone releasing hormone compositions |
| 09/02/2004 | US20040171572 Complex cationic lipids having quaternary nitrogens therein |
| 09/02/2004 | US20040171570 Polycyclic sugar surrogate-containing oligomeric compounds and compositions for use in gene modulation |
| 09/02/2004 | US20040171569 that directs formation of a recombinant virus upon introduction into a cell |
| 09/02/2004 | US20040171568 oligonucleotide at least 29 nucleotides in length, wherein the anti-HIV activity of said oligonucleotide occurs principally by a non-sequence complementary mode of action |
| 09/02/2004 | US20040171565 vaccines that express derivatives of ADP-ribosyltransferase toxins that display significantly reduced, or are deficient in, intrinsic ADP-ribosyltransferase activity (i.e. herein referred to as mARTs) and yet retain adjuvanticity |
| 09/02/2004 | US20040171549 Method of inhibiting angiogenesis or invasion or formation of metastases |
| 09/02/2004 | US20040171547 inhibiting the growth of a cancerous cell by contacting cell with an effective amount of a RhoB protein, or a variant of the RhoB protein; alone or in combination with additional anti-cancer agents, such as cytotoxic agents (e.g., 5-flurouracil) |
| 09/02/2004 | US20040171546 Regulation of lung tissue by hedgehog-like polypeptides and formulations and uses related thereto |
| 09/02/2004 | US20040171539 Regulation of human protein kinase-like protein |
| 09/02/2004 | US20040171538 Anticoagulants and their uses |
| 09/02/2004 | US20040171537 Adapter gene |
| 09/02/2004 | US20040171533 Methods and compositions for regulating adiopocytes |
| 09/02/2004 | US20040171159 Cell-specific adenovirus vector comprising EBV-specific promoter |
| 09/02/2004 | US20040171147 Cytotherapeutics, cytotherapeutic units and methods for treatments using them |
| 09/02/2004 | US20040171146 Adipose-derived stem cells and lattices |
| 09/02/2004 | US20040171123 fusion protein of an antibody that binds to human epidermal growth factor receptor-2 (HER2) and albumin with long shelf-life; stabilizing therapeutic proteins such as antibodies by conjugating them to albumin |
| 09/02/2004 | US20040171122 Gm-csf and/or defensin protein expression regulators in epithelial cells comprising ets transcription factor or gene encoding the same |
| 09/02/2004 | US20040171115 Comprises hematopoietic protein modulator for use in proliferation and diffefrentiation of bone marrow cells |
| 09/02/2004 | US20040171111 Polypeptide of a p53 protein-specific murin a/t-cell receptor, nucleic acids coding therefor and use thereof |
| 09/02/2004 | US20040171110 Novel member of the lysyl oxidase gene family |
| 09/02/2004 | US20040171108 Human excitatory amino acid transporter-2 gene promoter and uses thereof |
| 09/02/2004 | US20040171059 Comprises nucleotide sequences coding enzymatic polypeptide associated with programed cell death for identifying modulators for treatment of inflammatory, neurodegenerative and cell proliferative disorders |
| 09/02/2004 | US20040171033 Comprises modified nucleotide sequences for use in gene expression inhibition, viral defense, transposon silencing and treatment of metabolic disorders; antisense agents |
| 09/02/2004 | US20040171032 Non-phosphorous-linked oligomeric compounds and their use in gene modulation |
| 09/02/2004 | US20040171029 Comprises nucleotide sequences for use in gene expression inhibition, viral defense, transposon silencing and treatment of metabolic disorders; antisense agents |
| 09/02/2004 | US20040171018 Mouse farnesoid x receptor sequences for use in comparative pharmacology |
| 09/02/2004 | US20040170999 Nuclear hormone receptor ligand binding domain |
| 09/02/2004 | US20040170994 DNA sequences for human tumour suppressor genes |
| 09/02/2004 | US20040170993 Methods for diagnosing and treating heart disease |
| 09/02/2004 | US20040170972 comprises DNA vaccine, a recombinant vaccine, and a T cell epitope vaccine; includes use of serological diagnosis; genetic engineering |
| 09/02/2004 | US20040170971 kits for detecting amplification or elevated expression for diagnosis; genetic engineering; solid phase synthesis |
| 09/02/2004 | US20040170961 for drug screening anticancer agents; solid phase synthesis; animal models; genetic engineering; kits |
| 09/02/2004 | US20040170959 Methods for identifying antiviral oligonucleotides |
| 09/02/2004 | US20040170653 recognised by CD8-positive cytotoxic T-lymphocytes as a peptide antigen and causes a CTL-induced lysis and/or apoptosis of tumor or leukemia cell; has the amino acid sequence LLGDLFGV, which corresponds to the amino acid positions 81 to 88 of the hdm2 proto-oncoprotein |
| 09/02/2004 | US20040170646 Preferred are EB1 or EB14 cell; canary poxvirus containins a exogenous DNA sequence that encodes a tumor antigen, an antigen derived from a human pathogen, or a fragment thereof; vaccines |
| 09/02/2004 | US20040170644 Mixture of peptides derived from e6 and/or e7 papillomavirus proteins and uses thereof |
| 09/02/2004 | US20040170619 contacting a nucleic acid binding polypeptide, preferably a zinc finger polypeptide, with a nucleic acid sequence in the primary cell to regulate its expression; |
| 09/02/2004 | US20040170616 transferring a gene to preselected vertebrate cells by accelerating microprojectiles carrying polynucleic acid sequences having a regulatory sequence in the 5' to 3' direction and a gene downstream from the sequence at the cells to penetrate them and deposit the polynucleic acid sequences therein. |
| 09/02/2004 | US20040170615 Methods and compositions using compounds from fetal cells and tissues to improve condition of skin |
| 09/02/2004 | US20040170613 Compositions and methods for liver growth and liver protection |
| 09/02/2004 | US20040170611 culturing an autologous or allogenic dermal papilla cell in the presence of a Wnt polypeptide or a fragment or analog thereof, and grafting the cultured cell onto the skin |
| 09/02/2004 | US20040170607 Reducing viability of tumor cells by administering a virus; differential sensitivity using interferons |
| 09/02/2004 | US20040170606 Vaccines; medical diagnosis; detection antigen of papilloma virus ; genetic engineering fusion proteins; induce immunology response |
| 09/02/2004 | US20040170605 Activation gene expression of slug gene; transplant or gene therapy; sexual disorders; fertility |
| 09/02/2004 | US20040170601 Administering cytokines |
| 09/02/2004 | CA2516486A1 Method of treating ischemic disease |
| 09/02/2004 | CA2516371A1 Method of diagnosis of type 2 diabetes and early onset thereof |
| 09/02/2004 | CA2516320A1 Induced activation in dendritic cells |
| 09/02/2004 | CA2516304A1 Combination therapy for treating protein deficiencies |
| 09/02/2004 | CA2515779A1 Contraceptive method and compositions related to proteasomal interference |
| 09/01/2004 | EP1451856A2 Methods of promoting uptake and nuclear accumulation of polyamides in eukaryotic cells |
| 09/01/2004 | EP1451590A2 Peptides and method for detecting alzheimer's disease and differentiating alzheimer's disease from other demential diseases |